

B PHARM
(SEM VIII) THEORY EXAMINATION 2022-23
PHARMACOVIGILANCE

Time: 3 Hours

Total Marks: 75

Note: Attempt all Sections. If require any missing data; then choose suitably.

SECTION A

1. Attempt all questions in brief. 2 x 10 = 20

- (a) Define the adverse drug reaction.
- (b) Compute the limitations of detecting ADRs in clinical trials.
- (c) Discuss the PSUR.
- (d) Classify ADRs according to severity.
- (e) List out factors affecting adverse effects of the vaccine.
- (f) What is phase IV of clinical trials?
- (g) What are CIOMS working groups?
- (h) Discuss the cohort study with example.
- (i) Discuss the Defined daily doses.
- (j) Illustrate the importance of Pharmacogenomics.

SECTION B

2. Attempt any two parts of the following: 10 x 2 = 20

- (a) Differentiate between adverse drug reactions and adverse events with suitable examples. Explain the mechanisms of Type-A and Type-B ADRs.
- (b) Illustrate the vaccine safety surveillance along with the different types of pharmacovigilance methods used for passive and active surveillance.
- (c) Explain the drug safety evaluation in pediatrics and geriatrics.

SECTION C

3. Attempt any five parts of the following: 7 x 5 = 35

- (a) Characterize the different methods of causality and severity assessment of ADRs and explain Naranjo's scale.
- (b) Demonstrate the prerequisite for setting up a pharmacovigilance center in a CRO and hospital.
- (c) Define vaccine. Explain reasons for vaccination failure.
- (d) Summarize the ATC classification of drugs with example.
- (e) Explore the Pre- marketing and Post-marketing clinical trials.
- (f) Illustrate the organization and objectives of ICH.
- (g) Explain the Schedule Y of Drugs and Cosmetics Act in brief.